Goldman Sachs
SYRS

Goldman Sachs’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Goldman Sachs’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-262,373
Closed -$1.35M – 6137
2024
Q2 		$1.35M Sell
262,373
-184,218
-41% -$968K ﹤0.01% 4243
2024
Q1 		$2.39M Buy
446,591
+206,910
+86% +$1.43M ﹤0.01% 3742
2023
Q4 		$1.87M Buy
239,681
+133,149
+125% +$456K ﹤0.01% 3977
2023
Q3 		$421K Buy
106,532
+1,111
+1% +$4.16K ﹤0.01% 4730
2023
Q2 		$332K Buy
105,421
+189
+0.2% +$608 ﹤0.01% 4964
2023
Q1 		$281K Buy
105,232
+92,824
+748% +$360K ﹤0.01% 5145
2022
Q4 		$44.5K Buy
+12,408
New +$53.8K ﹤0.01% 5612
2022
Q3 		– Sell
-24,307
Closed -$234K – 6587
2022
Q2 		$234K Buy
24,307
+2,647
+12% +$24.8K ﹤0.01% 5570
2022
Q1 		$257K Sell
21,660
-27,829
-56% -$498K ﹤0.01% 5746
2021
Q4 		$1.61M Buy
49,489
+439
+0.9% +$17.8K ﹤0.01% 4426
2021
Q3 		$2.19M Sell
49,050
-1,072
-2% -$52.3K ﹤0.01% 4118
2021
Q2 		$2.73M Sell
50,122
-13,570
-21% -$803K ﹤0.01% 3921
2021
Q1 		$4.76M Buy
63,692
+51,904
+440% +$5.39M ﹤0.01% 3178
2020
Q4 		$1.28M Buy
11,788
+2,581
+28% +$236K ﹤0.01% 4041
2020
Q3 		$814K Buy
9,207
+2,920
+46% +$332K ﹤0.01% 4209
2020
Q2 		$670K Buy
6,287
+1,694
+37% +$152K ﹤0.01% 4213
2020
Q1 		$272K Sell
4,593
-567
-11% -$38.5K ﹤0.01% 4565
2019
Q4 		$357K Buy
5,160
+1,515
+42% +$91.9K ﹤0.01% 4679
2019
Q3 		$378K Buy
3,645
+1,776
+95% +$168K ﹤0.01% 4574
2019
Q2 		$173K Sell
1,869
-539
-22% -$37.5K ﹤0.01% 4834
2019
Q1 		$220K Buy
2,408
+37
+2% +$2.58K ﹤0.01% 4757
2018
Q4 		$132K Buy
2,371
+1,100
+87% +$83.6K ﹤0.01% 4947
2018
Q3 		$151K Sell
1,271
-5,203
-80% -$604K ﹤0.01% 4999
2018
Q2 		$661K Buy
6,474
+5,183
+401% +$642K ﹤0.01% 4346
2018
Q1 		$168K Buy
+1,291
New +$141K ﹤0.01% 5078
2017
Q1 		– Sell
-1,396
Closed -$170K – 7053
2016
Q4 		$170K Sell
1,396
-1,550
-53% -$217K ﹤0.01% 5876
2016
Q3 		$409K Buy
2,946
+946
+47% +$120K ﹤0.01% 5220
2016
Q2 		$363K Buy
+2,000
New +$363K ﹤0.01% 5171

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Goldman Sachs's SYRS Position: Q3 2024 in Review

Goldman Sachs sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 262,373 shares — an estimated $1.35M sold.

Goldman Sachs first reported a position in SYRS in Q2 2016 and held it in 28 quarters. The position peaked at $4.76M in Q1 2021. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

  • Goldman Sachs reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Goldman Sachs sold 262,373 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $1.35M.
  • Goldman Sachs first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2016 and held it in 28 quarters.
  • Goldman Sachs's Syros Pharmaceuticals, Inc. Common Stock position peaked at $4.76M in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.